Angion Biomedica Corp Stock News

BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Marc J. Wolfgang, M.S.

BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate and clinical updates.

ELTX is continuing its work on a KRAS vaccine in PDAC, with a phase 2 trial set to read out any day now. Earlier signals of efficacy of their phase 2 trial have shown biological correlation that suggests activity, but we still need to see outcomes of treatment. The company is heavily reliant on a positive read out in order to raise funds for further development.

SITC abstracts highlight updated immunogenicity results from the Phase 2 AMPLIFY-7P trial of ELI-002 7P and preclinical data on the use of intratumoral ELI-004 (AMP-CpG) for solid tumor immunotherapy ELI-002 7P induced mKRAS-specific T cell responses in 99% of evaluable patients (89/90), demonstrating potent and consistent immune activation Robust immune responses were elicited across all seven...

BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that the Company will present a late-breaking update on clinical immunogenicity results from its ongoing Phase 2 AMPLIFY-7P trial of ELI-002 in patients wi...

ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use among a diverse patient population Patients treated with ELI-002 7P represented a diverse HLA repertoire including 1,132 unique types identified among 1,398 total HLA backgrounds in assessed patients 99% (88/89) of patients assessed for HLA background induced mKRA...

BOSTON, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the planned initiation of an investigator-initiated Phase 1 neoadjuvant study of ELI-002 7P in combination with chemotherapy and an anti-PD1 checkpoint in...

BOSTON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on September 15, 2025, Elicio granted an aggregate of 9,800 inducement stock options to two new employees, as an inducement material to each individu...